- Home
- ACAD vs GBDC Comparison
ACAD vs GBDC Comparison
Compare ACAD & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- GBDC
- Stock Information
- Founded
- ACAD 1993
- GBDC 2009
- Country
- ACAD United States
- GBDC United States
- Employees
- ACAD N/A
- GBDC N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- GBDC Finance: Consumer Services
- Sector
- ACAD Health Care
- GBDC Finance
- Exchange
- ACAD Nasdaq
- GBDC Nasdaq
- Market Cap
- ACAD 3.4B
- GBDC 4.0B
- IPO Year
- ACAD 2004
- GBDC 2010
- Fundamental
- Price
- ACAD $19.95
- GBDC $15.83
- Analyst Decision
- ACAD Buy
- GBDC Buy
- Analyst Count
- ACAD 19
- GBDC 4
- Target Price
- ACAD $25.33
- GBDC $16.38
- AVG Volume (30 Days)
- ACAD 1.6M
- GBDC 1.5M
- Earning Date
- ACAD 02-26-2025
- GBDC 02-04-2025
- Dividend Yield
- ACAD N/A
- GBDC 9.84%
- EPS Growth
- ACAD N/A
- GBDC N/A
- EPS
- ACAD 0.78
- GBDC 1.38
- Revenue
- ACAD $929,236,000.00
- GBDC $780,607,000.00
- Revenue This Year
- ACAD $36.88
- GBDC $23.90
- Revenue Next Year
- ACAD $8.01
- GBDC N/A
- P/E Ratio
- ACAD $25.70
- GBDC $11.54
- Revenue Growth
- ACAD 47.06
- GBDC 23.71
- 52 Week Low
- ACAD $14.15
- GBDC $14.05
- 52 Week High
- ACAD $26.56
- GBDC $17.72
- Technical
- Relative Strength Index (RSI)
- ACAD 60.25
- GBDC 58.29
- Support Level
- ACAD $19.52
- GBDC $15.77
- Resistance Level
- ACAD $20.29
- GBDC $16.01
- Average True Range (ATR)
- ACAD 0.68
- GBDC 0.18
- MACD
- ACAD 0.08
- GBDC 0.01
- Stochastic Oscillator
- ACAD 72.62
- GBDC 80.00
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.